General Information of the Protein
Protein ID
PT01071
Protein Name
Tyrosine-protein kinase ABL1
Secondarily
Protein Name
Abelson murine leukemia viral oncogene homolog 1
Abelson tyrosine-protein kinase 1
Proto-oncogene c-Abl
p150
Gene Name
ABL1
Secondarily
Gene Name
ABL
JTK7
Sequence
MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAEHRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLFSALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSPKPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSASCVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTVTPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGSALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPPPPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVLPATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPERIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNKFAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
TK protein kinase group
>
Tyrosine protein kinase Abl family
Function
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9 (PubMed:22810897). Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' (PubMed:28428613). ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner (By similarity). Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity).
    Show/Hide
Uniprot ID
Primary ID:
P00519

Secondarily ID:
A3KFJ3
Q13869
Q13870
Q16133
Q17R61
Q45F09
    Show/Hide
Ensembl ID
ENSG00000097007
HGNC ID
HGNC:76
Subcellular Location
Cytoplasm
Cytoskeleton
Nucleus
Mitochondrion
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000045 , A-375
Compound ID Compound Name Compound Formula
CP0672877
1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea
   Show/Hide
C23H29FN6O
 1
1
IC50 = 380 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0002230
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
   Show/Hide
C28H22F3N7O
 19
1 IC50 < 2.54 nM
2 IC50 = 5.56 nM
3 IC50 = 18.5 nM
4 IC50 = 30 nM
5 IC50 = 38 nM
6 IC50 = 9170 nM
7 Kd = 3.6 nM
8 Kd = 4.9 nM
9 Kd = 10 nM
10 Kd = 12 nM
11 Kd = 13 nM
12 Kd = 14 nM
13 Kd = 15 nM
14 Kd = 18 nM
15 Kd = 21 nM
16 Kd = 36 nM
17 Kd = 56 nM
18 Kd = 660 nM
19 Kd > 10000 nM
CP0113988
CEP-32496
   Show/Hide
C24H22F3N5O5
 2
1 IC50 = 6 nM
2 Kd = 2.8 nM
CP0002778
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
   Show/Hide
C29H31N7O
 48
1 IC50 = 25 nM
2 IC50 = 38 nM
3 IC50 = 40 nM
4 IC50 = 98 nM
5 IC50 = 110 nM
6 IC50 = 170 nM
7 IC50 = 188 nM
8 IC50 = 190 nM
9 IC50 = 200 nM
10 IC50 = 220 nM
11 IC50 = 234 nM
12 IC50 = 250 nM
13 IC50 = 300 nM
14 IC50 = 319 nM
15 IC50 = 658 nM
16 IC50 = 1000 nM
17 IC50 = 1100 nM
18 IC50 = 2700 nM
19 IC50 = 74000 nM
20 IC50 > 1000 nM
21 IC50 > 10000 nM
22 Kd = 1 nM
23 Kd = 1.1 nM
24 Kd = 1.8 nM
25 Kd = 2.2 nM
26 Kd = 2.5 nM
27 Kd = 5.9 nM
28 Kd = 8.3 nM
29 Kd = 8.5 nM
30 Kd = 12 nM
31 Kd = 14 nM
32 Kd = 21 nM
33 Kd = 24 nM
34 Kd = 35 nM
35 Kd = 44 nM
36 Kd = 62 nM
37 Kd = 65 nM
38 Kd = 77 nM
39 Kd = 92 nM
40 Kd = 110 nM
41 Kd = 130 nM
42 Kd = 170 nM
43 Kd = 580 nM
44 Kd = 6200 nM
45 Kd > 10000 nM
46 Ki = 13 nM
47 Ki = 37 nM
48 Ki = 7000 nM
CP0137907
2-(4-methylpiperazin-1-yl)-N-[4-methyl-5-[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]-1,3-thiazol-2-yl]acetamide
   Show/Hide
C25H27N7OS
 1
1 IC50 = 83.6 nM
CP0015544
3-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide
   Show/Hide
C18H13F3N4O2
 1
1 IC50 = 273 nM
CP0018808
4-(cyclopentylamino)-2-[(2,5-dichlorophenyl)methylamino]-N-[3-(2-oxo-1,3-oxazolidin-3-yl)propyl]pyrimidine-5-carboxamide
   Show/Hide
C23H28Cl2N6O3
 2
1 IC50 = 16360 nM
2 Kd = 740 nM
CP0001111
(2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol
   Show/Hide
C19H26N6O
 3
1 IC50 > 10000 nM
2 IC50 > 100000 nM
3 Kd > 10000 nM
CP0030881
SR-302
   Show/Hide
C32H42N6O5S
 1
1 IC50 > 25000 nM
CP0010193
AG-013736
   Show/Hide
C22H18N4OS
 14
1 Kd = 1.5 nM
2 Kd = 3.6 nM
3 Kd = 20 nM
4 Kd = 23 nM
5 Kd = 36 nM
6 Kd = 63 nM
7 Kd = 84 nM
8 Kd = 200 nM
9 Kd = 230 nM
10 Kd = 290 nM
11 Kd = 330 nM
12 Kd = 800 nM
13 Kd = 830 nM
14 Kd = 2600 nM
CP0019908
BDBM50242742
   Show/Hide
C30H40ClN7O3S
 15
1 Kd = 5.4 nM
2 Kd = 14 nM
3 Kd = 19 nM
4 Kd = 39 nM
5 Kd = 52 nM
6 Kd = 54 nM
7 Kd = 70 nM
8 Kd = 73 nM
9 Kd = 93 nM
10 Kd = 95 nM
11 Kd = 100 nM
12 Kd = 160 nM
13 Kd = 170 nM
14 Kd = 190 nM
15 Kd = 200 nM
CP0126678
N-(3-bromophenyl)-1-(2-chloro-2-phenylethyl)-6-(2-morpholin-4-ylethylsulfanyl)pyrazolo[3,4-d]pyrimidin-4-amine
   Show/Hide
C25H26BrClN6OS
 1
1 Ki = 120 nM
CP0070258
N-benzyl-1-(2-chloro-2-phenylethyl)pyrazolo[3,4-d]pyrimidin-4-amine
   Show/Hide
C20H18ClN5
 3
1 Ki = 370 nM
2 Ki = 371.54 nM
3 Ki = 400 nM
CP0130713
1-(2-chloro-2-phenylethyl)-N-(3-chlorophenyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
   Show/Hide
C20H17Cl2N5S
 1
1 Ki = 600 nM
CP0102858
1-[2-(4-bromophenyl)-2-chloroethyl]-N-phenylpyrazolo[3,4-d]pyrimidin-4-amine
   Show/Hide
C19H15BrClN5
 1
1 Ki = 610 nM
CP0157055
N-(3-bromophenyl)-6-methylsulfanyl-1-(2-phenylpropyl)pyrazolo[3,4-d]pyrimidin-4-amine
   Show/Hide
C21H20BrN5S
 1
1 Ki = 1070 nM
CP0096095
4-(azepan-1-yl)-1-[(E)-2-phenylethenyl]pyrazolo[3,4-d]pyrimidine
   Show/Hide
C19H21N5
 4
1 Km = 35310 nM
2 Km = 48000 nM
3 Km = 50000 nM
4 Km = 55100 nM
CP0096096
N-cyclohexyl-1-[(E)-2-phenylethenyl]pyrazolo[3,4-d]pyrimidin-4-amine
   Show/Hide
C19H21N5
 3
1 Km = 47500 nM
2 Km = 48300 nM
3 Km = 49800 nM
Clinical Information about the Protein
Target 1 ( Tyrosine-protein kinase ABL1 (ABL) )
Target Type Successful Target
Disease 8 Target-related Diseases  8
1 Breast cancer [ICD-11: 2C60-2C65]
2 Acute lymphoblastic leukaemia [ICD-11: 2A85]
3 Ischemia [ICD-11: 8B10-8B11]
4 Chronic myelogenous leukaemia [ICD-11: 2A20.0]
5 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
6 Chronic myeloid leukaemia [ICD-11: 2A20]
7 Acute myeloid leukaemia [ICD-11: 2A60]
8 Malnutrition [ICD-11: 5B50-5B71]
Approved Drug(s) 4 Approved Drugs  4
1 Bosutinib Approved
Breast cancer
2 Ponatinib Approved
Acute lymphoblastic leukaemia
3 SKI-758 Approved
Ischemia
4 Adenosine triphosphate Approved
Malnutrition
Clinical Trial Drug(s) 4 Clinical Trial Drugs  4
1 Flumatinib Phase 2
Chronic myelogenous leukaemia
2 Saracatinib Phase 2
Solid tumour/cancer
3 DCC-2036 Phase 1/2
Chronic myeloid leukaemia
4 KW-2449 Phase 1
Acute myeloid leukaemia
Target 2 ( ABL T315I mutant (ABL T315I) )
Target Type Patented-recorded Target
Target 3 ( ABL messenger RNA (ABL mRNA) )
Target Type Discontinued Target
Similar Protein(s) and Bioactivity Statistics
50% Identity
Protein ID Protein Name Protein Organism
PT01392 Tyrosine-protein kinase ABL2 Homo sapiens, Human